|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.80 - 7.85|
|52 Week Range||4.20 - 9.98|
|PE Ratio (TTM)||31.28|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
In a prior multicenter, randomized, controlled clinical trial (RCT), application of our viable cryopreserved placental membrane product, Grafix®, to chronic diabetic foot ulcers (DFUs) resulted in a significantly higher proportion of wound closure by 12 weeks compared to control (62% vs. 21%)1. Although RCTs remain the gold standard to determine treatment efficacy, RCT results may not accurately reflect the effectiveness of therapies in real-world practice. Results in effectiveness studies may differ from results observed in tightly controlled experimental conditions of an efficacy study, as broader populations of patients and clinicians have access to products.
COLUMBIA, Maryland, April 24, 2018-- Osiris Therapeutics, Inc., a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will ...
SAN DIEGO, CA / ACCESSWIRE / November 28, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors who purchased NASDAQ: OSIR shares against Osiris Therapeutics, ...
A former chief financial officer of biotechnology company Osiris Therapeutics on Thursday pleaded guilty to making false statements to auditors to inflate the company's reported revenue. Philip Jacoby, 65, entered his plea before U.S. District Judge Denise Cote in in Manhattan, while Osiris separately agreed to pay $1.5 million to settle a related civil lawsuit by the U.S. Securities and Exchange Commission, court records showed. As part of the plea, Jacoby and prosecutors agreed that an appropriate sentence under federal guidelines would be four to 10 months in prison and a fine of up to $5 million.